ArticleCureus2026
Low-Positive Myelin Oligodendrocyte Glycoprotein (MOG)-Immunoglobulin G (IgG) in Pediatric Demyelinating Disease: How Imaging Features Can Support a MOG Antibody-Associated Disease (MOGAD) Diagnosis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare inflammatory demyelinating disorder that can affect children and remains challenging to diagnose. Neuroimaging plays a key role, as MRI patterns in the brain, optic nerves, and spinal cord differ from those of multiple sclerosis and Aquaporin-4 (AQP4)‑positive neuromyelitis optica spectrum disorder (NMOSD). The 2023 international consensus criteria require a compatible core clinical phenotype, positive serum MOG‑immunoglobulin G (IgG), and exclusion of a better alternative diagnosis, with supportive MRI features when needed. The authors recently managed a pediatric patient with an acute demyelinating syndrome, positive serum MOG‑IgG, and characteristic compatible lesions. This case illustrates key clinical and imaging features of pediatric MOGAD, shows how the 2023 criteria can be applied in practice, and highlights radiologic clues that help distinguish MOGAD from other demyelinating disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.